2024-519270-40-00
EU Clinical Trials Information System
- Trial ID
- T-ctis-2024-519270-40-00
- Registry
- EU Clinical Trials Information System
- CTIS number
- 2024-519270-40-00
- Asset
- HLP003
- Sponsor, as registered
- Cybin IRL Limited
- Phase
- Therapeutic confirmatory (Phase III)
- Indication
- Major Depressive Disorder
- Status
- Authorised
- Start date
- 30/10/2025
- Primary completion
- CTIS does not publish one.
- Member states concerned
- Czechia, Germany, Greece, Ireland, Poland
- Sites
- 17
Member states whose regulator has a decision on this trial.
euclinicaltrials.euctis registryverified 2026-10-06
Notes on the record
countries is memberStatesConcerned, i.e. every member state the trial is filed in; site_count sums trialSites across authorised Part II sections (IE 2, DE 4, CZ 3, PL 5, GR 3). primary_completion_date is EMPTY because CTIS does not publish a primary completion date; it is not unknown, it is not a field the registry has. Per-state authorisation is NOT recorded: mscPublicStatusCode takes values [2, 4] on this record and the registry publishes no key for them, so decoding it would be a guess. Read from the CTIS public API retrieve endpoint 2026-10-06. EMBRACE (CYB003-003); secondaryIdentifyingNumbers names NCT06793397. Overall decision 2025-08-05; lastDecisionDate on all five member states falls 18 to 22 September 2026; publishDate 2026-09-25. Part I subject count 189; Part I countries outside the EU: US, UK, Canada, Australia. Same field rules as sibling T-ctis-2024-516805-22-00.
Company
Through HLP003: Helus Pharma
Cited in
No published issue cites this registry number.